Thomas Cahill is a physician-scientist with an M.D. and Ph.D. from Duke University who co-founded Newpath Partners, where he operates as a founding investor that creates companies around transformational scientific discoveries by partnering early with academic stars like David Liu and Ben Cravatt. His distinctive founder of founders model goes beyond standard venture capital by explicitly structuring companies to align interests between academic scientists, investors, and management teams, positioning him as a go-to partner for cutting-edge platform science in gene editing, epigenetics, and cell-state biology.